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Abstract
Background: Aboriginal status has been unreliably and incompletely recorded in health and vital registration data
collections for the most populous areas of Australia, including NSW where 29% of Australian Aboriginal people reside.
This paper reports an assessment of Aboriginal status recording in NSW cancer registrations and estimates incidence,
mortality and survival from cancer in NSW Aboriginal people using multiple imputation of missing Aboriginal status in
NSW Central Cancer Registry (CCR) records.
Methods: Logistic regression modelling and multiple imputation were used to assign Aboriginal status to those
records of cancer diagnosed from 1999 to 2008 with missing Aboriginality (aﬀecting 12-18% of NSW cancers registered
in this period). Estimates of incidence, mortality and survival from cancer in NSW Aboriginal people were compared
with the NSW total population, as standardised incidence andmortality ratios, and with the non-Aboriginal population.
Results: Following imputation, 146 (12.2%) extra cancers in Aboriginal males and 140 (12.5%) in Aboriginal females
were found for 1999-2007. Mean annual cancer incidence in NSW Aboriginal people was estimated to be 660 per
100,000 and 462 per 100,000, 9% and 6% higher than all NSWmales and females respectively. Mean annual cancer
mortality in NSW Aboriginal people was estimated to be 373 per 100,000 in males and 240 per 100,000 in females,
68% and 73% higher than for all NSWmales and females respectively. Despite similar incidence of localised cancer,
mortality from localised cancer in Aboriginal people is signiﬁcantly higher than in non-Aboriginal people, as is
mortality from cancers with regional, distant and unknown degree of spread at diagnosis. Cancer survival in Aboriginal
people is signiﬁcantly lower: 51% of males and 43% of females had died of the cancer by 5 years following diagnosis,
compared to 36% and 33% of non-Aboriginal males and females respectively.
Conclusion: The present study is the ﬁrst to produce valid and reliable estimates of cancer incidence, survival and
mortality in Australian Aboriginal people from NSW. Despite somewhat higher cancer incidence in Aboriginal than in
non-Aboriginal people, substantially higher mortality and lower survival in Aboriginal people is only partly explained
by more advanced cancer at diagnosis.
Background
Historically, Aboriginality has been unreliably and incom-
pletely recorded in health and vital registration data
collections for the most populous areas of Australia,
including NSW, the most heavily populated state where
one third of the Australian population and 29% of
Australia’s Aboriginal people reside [1]. According the the
*Correspondence: stephen.morrell@cancerinstitute.org.au
1Cancer Institute NSW Level 9, 8 Central Ave, Australian Technology Park,
NSW, 2015, Australia
2School of Public Health and Community Medicine Samuels Building,
University of NSW Randwick, NSW, 2052, Australia
2006 Australian census, Aboriginal people numbered ≈
148,000 in NSW and made up 2.2% of the state’s ≈
6,800,000 population. A high proportion of NSW
Aboriginal people live in urban areas in which over half
the NSW population resides, but comprise a smaller frac-
tion of the urban population than they do of populations
in rural and remote areas.
Australian Aboriginal people suﬀer disproportionately
higher morbidity and mortality than the non-Aboriginal
population [2]. However the extent of illness andmortality
in Aboriginal people, including from cancer, is known reli-
ably only in the Northern Territory (NT), South Australia
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(SA) and Western Australia (WA), and often has been
inferred for all Australian Aboriginal people from these
sources. Cancer mortality for Aboriginal people in NSW
has been estimated previously for 1994-2002 [3], and was
found to be signiﬁcantly higher than for NSW overall,
by 71% in males and by 65% in females. Lung, colorec-
tal and stomach cancer in both sexes, oesophageal cancer
in males, and cervical, pancreatic and kidney cancer in
females, were the main cancers responsible for the overall
cancer mortality excess in NSW.
A 2010 Queensland study of Aboriginal cancer inci-
dence and mortality for 1997-2006 found incidence over-
all to be 28% and 15% lower compared to all Queensland
males and females respectively, but mortality was esti-
mated to be 28% higher in males and 47% higher in
females [4]. Mortality from cervical, uterine, lung and
head and neck cancer was particularly elevated in Abo-
riginal females, and oesophageal, head and neck, liver and
lung cancers were responsible for most of the excess in
Aboriginal males.
Reliable estimates of cancer incidence in NSW Abo-
riginal people, however, are absent. This has been due
predominantly to under-reporting of Aboriginal status in
those parts of the health systemwhere cancer is diagnosed
and treated. From 1994 proportions of cancers with miss-
ing Aboriginal status decreased due to measures taken in
the early 1990s nationally to remedy under-recording of
Aboriginal status in death registration. In the mid-1990s
NSW Health introduced measures to improve recording
of Aboriginality in the NSW health system, particularly
for hospital admissions. Consequently, Aboriginal sta-
tus on cancer registration of living cases in particular
in NSW has also improved, but until now the extent of
the improvement has not been assessed, and reliable esti-
mates of Aboriginal cancer incidence in NSW have yet to
be produced.
The purpose of this paper then is to report:
• (brieﬂy) on an assessment of Aboriginal recording in
NSW cancer registration data
• results from the imputation of Aboriginality in NSW
cancer records with missing Aboriginal status
• reliable estimates of incidence, mortality and survival
from cancer in NSW Aboriginal people.
Methods
Study design
Observational comparative cross-sectional study of the
whole Aboriginal population of NSW with the non-
Aboriginal population and with the NSW population
overall, 1999-2007.
Data andmaterials
All (de-identiﬁed) records of invasive cancers diagnosed
from 1999 to 2008 held on theNSWCCRwere used in this
study. Cancers included in the analysis were ICD-10 codes
C00-C96, D45, D46, D47.1, D47.3 and non-melanoma
skin cancer (C44) was excluded. In order to estimate inci-
dence and minimise recording bias of Aboriginal status in
NSW cancer data, logistic regression modelling of cancer
records with non-missing Aboriginal status was used to
inform a multiple imputation (MI) approach to assigning
Aboriginal status to those records where Aboriginality is
missing. Cancers diagnosed from 1999 onwards were cho-
sen for imputation and analysis since the proportions of
records with missing Aboriginal status were lowest from
then (Figure 1). Cancer mortality data as recorded by the
CCR from 1994 onwards are considered suﬃciently reli-
able to use, but for this paper we have estimated Aborigi-
nal cancer mortality for 1999-2007, to inform the survival
analysis of cancers diagnosed over 1999-2007.
Analysis
Essentially, MI is a means for representing uncertainty in
missing data, by producing a distribution of plausible val-
ues for a missing variable in a record, given the values of
that record’s non-missing covariates. The contribution of
the non-missing covariates to the distribution of missing
values is based on modelling the non-missing co-variates
in complete cases to predict the likely value of the variable
in records where it is missing.
The key assumption of most methods for handling
missing data is that of Missing Completely at Random
(MCAR), which essentially means that the observations
that are missing are a simple random sample of all obser-
vations. This is clearly not the case for Aboriginal status.
However,MI requires only themore relaxed assumption
of Missing at Random (MAR), which means that the miss-
ing data is a random sample of all the data after adjusting
for all other observed (non-missing) variables [5]. In other
words, systematic diﬀerences between missing cases and
the complete cases are allowed so long as all (or most) of
the diﬀerences can be explained or modelled by the other
observed variables. If the proportion of missingness in the
records is low then multiple imputation can be used [6].
Once a model predicting values for a missing variable
is constructed, Markov chain Monte Carlo (MCMC) sim-
ulation is used to create a small number of independent
draws (typically 5-10) of records with a range of imputed
values from the predictive distribution. Each draw rep-
resents a random sample of the missing values and is
then used for multiple-imputation inference such that a
number of data sets (equal to the number of draws) of
‘complete’ cases are analysed using standard statistical
analyses. The results from the ‘complete’ data sets are then
combined to produce inferences that account for multi-
ple records of the same individual from the draws. The
overall estimate is the average of the individual estimates,
and the overall standard errors include both between
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Figure 1 Proportion (%) of Aboriginal status missing in NSW cancer registrations by alive/dead status of cancer case.
and within imputation standard errors. Standard errors
for the missing variable reﬂect the uncertainty due to the
missing values, leading to valid statistical inferences.
MI is particularly suitable for estimating Aboriginal can-
cer rates, as there are numerous covariates available in
the NSW CCR (such as area of residence, sex, age, coun-
try of birth and clinical variables) which make it quite
likely that the MAR assumption would be met. For can-
cer mortality, missing Aboriginal status has been very low
on the NSW CCR since 1999, ranging between 0.2% and
2.8% over 1999-2007 (cf. Figure 1). Accordingly, multiple
imputation was applied to cancer incidence data only.
The statistical modelling approach used to develop
the imputation model for the MI procedure was logistic
regression, since the missing variable is a binary quan-
tity. No covariates other than Aboriginality had missing
values, which simpliﬁed the estimation procedure con-
siderably. Covariates included in the model were 5-year
age group, sex, country of birth, cancer degree of spread
at diagnosis, clinical grouping, one-year survival, Area
Health Service of residence at diagnosis, and percentage
of the local government area population identifying as
Aboriginal in the most recent population census. Area
Health Service was included to capture geographical
remoteness and diﬀerences in health resources and access
to health services. The logistic regressionmodel was ﬁtted
to all cancer data with non-missing Aboriginal status for
1999-2008, treating Aboriginal status as a binary outcome
(1 = Aboriginal or Torres Strait Islander, 0 = otherwise).
For the logistic regression modelling and imputation,
we used Proc Logistic, Proc MI and Proc MIAna-
lyze in SAS/STAT software, version 9.2. Directly age-
standardised cancer incidence and mortality rates were
calculated using the 2001 Australian census population
as the standard. Indirectly age-standardised incidence
and mortality ratios were calculated using cancer inci-
dence and mortality expected in the whole NSW male or
female population, as appropriate, for 1999-2007. Cumu-
lated risks of cancer incidence and mortality to age 75
years were calculated according to the method of Day [7].
Cox proportional hazards regression modelling was used
to produce cancer-speciﬁc hazard ratios by Indigenous
status by sex, adjusted for age and year of diagnosis, and
cancer degree of spread at diagnosis.
A sensitivity analysis was conducted in which 0-5% ran-
dom samples of all cancers with missing Aboriginal status
were assigned as Aboriginal and overall Indigenous cancer
incidence estimated with these added to cancers recorded
as Indigenous.
The Cancer Institute NSW is the organisation with
delegated authorisation to manage the NSWCentral Can-
cer Registry on behalf of the NSW Ministry of Health.
The management of this registry includes assessment,
review, maintenance and enhancement of the quality of
all data held in the registry. The work for this project was
undertaken within this ambit. In addition, no identiﬁed
individual case information was utilised. Therefore formal
ethical approval was not required to undertake this work.




As Figure 1 indicates, Aboriginal status on cancer reg-
istration in NSW has improved considerably since the
mid-1990s: for cancer deaths, missing Aboriginal status
aﬀects 1-2% of cases diagnosed since 1999 (the rise for
2008 is artefactual due to CCR death information yet to
be fully updated from the Australian Bureau of Statistics).
For still-living cancer cases, the proportion with unknown
Aboriginality status declined sharply from 75% in 1996
to 30% in 1999 and steadily thereafter to under 20% by
2008. For all registered cancers, the proportion with miss-
ing Aboriginal status varied between 12% and 14% over
1998-2007. While there is still a substantial proportion of
missing Aboriginal status in live cancers this is not so great
as to preclude multiple imputation. From the perspective
of care episodes, proportions of missing Aboriginal sta-
tus in alive cancer cases are generally around 90% if no
inpatient hospital admission occurs, but declines to 10-
20% by the ﬁrst hospital admission for the cancer, then to
negligible levels by the fourth admission (Figure 2).
Model used in multiple imputation
From the logistic regression model applied to cancer
records with known Aboriginal status, most of the odds
ratio estimates were statistically signiﬁcant (Table 1). All
age groups of cancer diagnosis younger than 75+ years
were positively and signiﬁcantly associated with Aborig-
inality, as were distant and regional degree of cancer
spread, death within 1 year of diagnosis, percentage of
Aboriginal population in the local government area of res-
idence (at diagnosis), and non-metropolitan NSW Area
Health Services with relatively high Aboriginal population
compositions. Signiﬁcant negative predictors included
country of birth outside Australia, and most cancer clin-
ical groupings (using respiratory cancer as the referent).
The concordance from the logistic regression model was
74.4% and the percentage discordant was 20.0%, leaving
5.6% tied. The resulting area under the ROC curve of 0.772
suggests that the model correctly predicts Aboriginal sta-
tus in most cases.
Cancer Incidence
After imputation, 146 additional cancers diagnosed in
1999-2007 were assigned as Aboriginal in males (12.2%
more than recorded), and 140 cases to females (12.5%
more than recorded). Mean annual Aboriginal cancer
incidence was estimated to be 660 per 100,000 in males
and 462 per 100,000 in females, equivalent to 9% and 6%
higher than all NSW males and females respectively, as
measured by standardised incidence ratios (Tables 2 and
3). Head and neck (SIR = 2.05, males and 2.01, females),
oesophagus (1.85 and 2.16), liver (1.67 and 2.21) and lung
(1.93 and 2.43) were signiﬁcantly higher in both sexes.
Males also had signiﬁcantly higher incidence rates of can-
cers of unknown primary origin (SIR= 1.63) and stomach
(1.85). Females had a signiﬁcantly higher incidence of cer-
vical cancer (SIR = 2.43). Male and female Aboriginals
Figure 2 Inpatient admission episodes and proportion (%) of Aboriginal status missing in alive cancer cases, 1999-2007.
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Table 1 Predictors1 of Aboriginal status in NSW CCR registered cancers 1999-2007, from logistic regressionmodel
Predictor Predictor category OR (95% CI)2
Age group (yr) 0 - 4 3.73 (2.48 - 5.61)
5 - 9 4.43 (2.58 - 7.58)
10 - 14 2.13 (1.07 - 4.24)
15 - 19 3.45 (2.13 - 5.60)
20 - 24 3.54 (2.34 - 5.36)
25 - 29 3.35 (2.35 - 4.77)
30 - 34 2.85 (2.08 - 3.90)
35 - 39 4.05 (3.23 - 5.07)
40 - 44 3.88 (3.20 - 4.69))
45 - 49 3.30 (2.78 - 3.92)
50 - 54 3.16 (2.71 - 3.69)
55 - 59 2.55 (2.20 - 2.96)
60 - 64 2.46 (2.14 - 2.84)
65 - 69 1.88 (1.63 - 2.18)
70 - 74 1.59 (1.38 - 1.85)
75 + 1.00 (referent)
Sex Male 0.93 (0.85-1.02)
Female 1.00 (referent)
Country of Birth Not Australia 0.22 (0.19-0.25)
Unknown 0.90 (0.66-1.22)
Australia 1.00 (referent)




Clinical Grouping Skin 0.24 (0.19-0.31)
Head and Neck 1.11 (0.91-1.35)
Upper Gastrointestinal 0.87 (0.74-1.01)
Colorectal 0.54 (0.46-0.62)






Thyroid and other endocrine 0.44 (0.32-0.62)
Lymphohaematopoeitic 0.65 (0.54-0.77)
Ill-deﬁned and unknown primary sites 0.64 (0.52-0.79)
Respiratory 1.00 (referent)
One-year survival Death within 1 year from Diagnosis 1.36 (1.25-1.49)
Survival to 1 year from Diagnosis 1.00 (referent)
Area Health Service Sydney South West AHS 0.74 (0.63-0.87)
Sydney West AHS 0.86 (0.73-1.00)
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Table 1 Predictors1 of Aboriginal status in NSW CCR registered cancers 1999-2007, from logistic regressionmodel
(Continued)
Northern Sydney and Central Coast AHS 0.59 (0.50-0.70)
Hunter and New England AHS 1.29 (1.13-1.47)
North Coast AHS 1.28 (1.11-1.49)
Greater Southern AHS 1.21 (1.03-1.41)
Greater Western AHS 1.83 (1.56-2.13)
South Eastern Sydney and Illawarra AHS 1.00 (referent)
Percentage Aboriginal in
Local Government Area3 1.13 (1.12-1.15)
1Co-variates simultaneously adjusted for.
2Odds ratio and 95% conﬁdence interval.
3Of residence at diagnosis.
had signiﬁcantly lower incidence of melanoma (SIR =
0.44, males and 0.47 females). Incidence of prostate can-
cer (SIR = 0.82) was also signiﬁcantly lower than for all
NSW males, and thyroid cancer incidence was signiﬁ-
cantly lower in Aboriginal females (SIR = 0.54). Prostate
cancer is the most commonly diagnosed cancer in Abo-
riginal males (145 per 100,000), followed by lung can-
cer (111 per 100,00) and large bowel (75 per 100,000).
Breast cancer is the most common cancer diagnosed in
Aboriginal females (116 per 100,000), followed by lung
(69 per 100,000), and cancer of the large bowel (56 per
100,000). The cumulative risk of cancer over ages 0 to 75
years in Aboriginal males was 1 in 2.6, compared to 1 in
2.8 for non-Aboriginal males; in Aboriginal females the
cumulative risk was 1 in 3.5, compared to 1 in 3.8 for
non-Aboriginal females.
The age distribution of cancer incidence in Aboriginal
people showsmost of the excess over non-Aboriginal peo-
ple to be occurring in the oldest age groups, manifesting
by age 70+ years (Figure 3). By age 75+ years cancer inci-
dence in Aboriginal people is approximately 30% and 40%
higher in males and females respectively.
Cancer Mortality
Mean annual cancer mortality in NSW Aboriginal peo-
ple is estimated to be 373 per 100,000 in males (from
657 deaths over 1999-2007), and 240 per 100,000 in
females (from 572 deaths; Tables 4 and 5). Cancer mor-
tality in Aboriginal people was 68% and 73% higher
than in all NSW males and females respectively, as
measured by standardised mortality ratios. The higher
excess mortality over incidence indicates considerably
lower cancer survival. Outcomes for Aboriginal males
with prostate cancer are particularly poor: despite 18%
lower incidence of prostate cancer than for NSW over-
all, Aboriginal males have 86% higher prostate can-
cer mortality. Mortality from cervical cancer, one of
the few easily preventable, was 374% higher in Abo-
riginal than all NSW women, considerably surpassing
the 143% excess incidence of cervical cancer (Table 5).
Aboriginal mortality is substantially higher than NSW
from several other key cancers including lung (SMR =
1.99, males and 2.73, females), female breast (SMR =
1.54). Even for melanoma, with standardised incidence
ratios of 0.44 for males and 0.47 for females, the standard-
ised mortality ratios were not signiﬁcantly diﬀerent from
1 (0.67 in males, 1.00 in females).
Lung cancer is the leading cause of cancer death in
Aboriginal males (91 per 100,000), followed by prostate
cancer (57 per 100,000) and large bowel (39 per 100,000)
(Table 4). Lung cancer is also the most common cancer
cause of death in Aboriginal females (58 per 100,000), fol-
lowed by breast (36 per 100,000) and large bowel (24 per
100,000) (Table 5). The cumulative risk of cancer mortal-
ity over ages 0 to 75 years in Aboriginal males was 1 in 4.7,
compared to 1 in 7.5 for non-Aboriginal males; in Aborig-
inal females the cumulative risk of cancer mortality was 1
in 6.5, compared to 1 in 11.1 for non-Aboriginal females.
As for incidence, the age distribution of cancer mortal-
ity in Aboriginal people shows most of the excess over
non-Aboriginal people occurring in the oldest age groups,
except the excess mortality manifests earlier at 60+ years
(Figure 3). By age 75+ years cancer mortality in Aborigi-
nal people is approximately 80% higher in males and 75%
higher in females.
Cancer degree of spread
Diﬀerences in cancer stage at diagnosis are evident but
indicate only some of the sources of diﬀerences between
Aboriginal and non-Aboriginal cancer mortality. Inci-
dence of cancer with regional or distant degree of spread
is signiﬁcantly higher in Aboriginal males and females
than non-Aboriginal counterparts, and mortality corre-
spondingly is signiﬁcantly higher (Figure 4). However,
while incidence by localised cancer in Aboriginal peo-
ple is somewhat lower (non-signiﬁcantly), and is non-
signiﬁcantly higher for cancer of unknown degree of
















Table 2 Estimates of cancer incidence in Aboriginal males, NSW, 1999-2007, and risk comparison with non-Aboriginal males
Cancer Registered Missing Imputed Imputed SIR1 Risk2 to age 75, 1 in:
site cases (%) cases incidence3 (95% CI) Non-
per 100,000 Aboriginal Aboriginal
(95% CI)
Head and neck 96 6.4 103 37.9 (28.5-47.2) 2.05 (1.64-2.46) 34 59
Oesophagus 27 2.2 28 13.6 (7.5-19.7) 1.85 (1.15-2.54) 86 174
Stomach 46 3.1 47 25.5 (16.7-34.3) 1.85 (1.32-2.38) 54 107
Large bowel 147 6.4 158 75.4 (60.6-90.3) 1.06 (0.88-1.23) 17 17
Liver 29 2.1 30 11.7 (6.9-16.6) 1.67 (1.06-2.27) 81 172
Pancreas 32 1.1 32 17.7 (10.2-25.1) 1.53 (1.00-2.06) 87 124
Lung 200 2.1 206 111.0 (92.6-129.4) 1.93 (1.66-2.19) 12 23
Melanoma of skin 37 41.2 67 33.6 (21.3-45.9) 0.44 (0.29-0.58) 48 23
Mesothelioma 11 1.7 11 7.4 (2.4-12.5) 1.32 (0.54-2.10) 211 276
Prostate 183 20.0 239 144.5 (120.0-169.0) 0.82 (0.71-0.94) 10 8
Kidney 50 9.1 53 24.1 (15.9-32.4) 1.31 (0.95-1.66) 60 73
Bladder 30 5.3 31 23.3 (13.7-33.0) 1.07 (0.69-1.45) 105 87
Brain 20 2.8 21 5.5 (2.2-8.8) 0.74 (0.42-1.07) 262 150
Non-Hodgkin’s lymphoma 47 10.2 53 17.1 (11.4-22.7) 0.95 (0.68-1.22) 62 60
Multiple myeloma 17 6.3 18 9.1 (3.9-14.2) 1.24 (0.65-1.83) 130 180
All leukaemias 51 8.6 56 23.8 (15.0-32.5) 1.06 (0.77-1.35) 70 83
Unknown primary 59 4.7 61 30.1 (20.7-39.5) 1.63 (1.21-2.05) 47 77
Myelodysplasia 27 6.1 29 18.1 (9.7-26.4) 1.50 (0.94-2.07) 118 157
All cancers 1,201 13.6 1,347 660.2 (613.7-706.6) 1.09 (1.02-1.15) 2.6 2.8
1Standardised incidence ratio in relation to all NSWmales.
2Cumulative risk.
















Table 3 Estimates of cancer incidence in Aboriginal females, NSW, 1999-2007, and risk comparison with non-Aboriginal females
Cancer Registered Missing Imputed Imputed SIR1 Risk2 to age 75, 1 in:
site cases (%) cases incidence3 (95% CI) Non-
per 100,000 Aboriginal Aboriginal
(95% CI)
Head and neck 36 8.0 39 13.1 (8.5-17.6) 2.01 (1.37-2.65) 81 193
Oesophagus 14 1.6 14 5.8 (2.4-9.1) 2.16 (1.03-3.29) 207 521
Stomach 18 3.6 19 8.2 (4.0-12.5) 1.35 (0.73-1.98) 173 253
Large bowel 110 7.7 120 56.0 (44.4-67.6) 0.95 (0.77-1.13) 29 26
Liver 15 1.7 15 6.4 (2.8-10.1) 2.21 (1.09-3.33) 213 533
Pancreas 28 1.5 29 14.4 (8.5-20.2) 1.49 (0.94-2.04) 119 166
Lung 162 3.1 167 68.7 (57.0-80.3) 2.43 (2.06-2.81) 19 44
Melanoma of skin 30 46.7 62 20.2 (12.9-27.4) 0.47 (0.31-0.62) 74 34
Breast 304 12.2 346 115.7 (101.2-130.3) 0.94 (0.84-1.05) 12 11
Cervix 65 12.4 71 19.0 (13.7-24.4) 2.43 (1.83-3.03) 69 186
Uterus 43 8.7 50 21.0 (14.2-27.8)) 1.16 (0.82-1.51) 65 77
Ovary 36 4.5 38 12.0 (7.5-16.4) 1.11 (0.74-1.47) 109 112
Kidney 31 10.0 34 12.9 (7.8-17.9) 1.33 (0.87-1.80) 105 140
Brain 22 2.5 23 6.8 (3.4-10.2) 1.08 (0.63-1.53) 174 235
Thyroid 24 12.2 28 6.5 (3.7-9.3) 0.54 (0.33-0.75) 173 107
Non-Hodgkin’s lymphoma 26 11.4 33 11.2 (6.4-16.1) 0.76 (0.48-1.04) 96 87
All leukaemias 30 8.3 33 10.3 (5.5-15.0) 0.89 (0.58-1.20) 203 142
Unknown primary 44 4.1 47 18.1 (12.1-24.2) 1.29 (0.90-1.68) 73 101
Myelodysplasia 14 8.2 16 6.9 (2.9-11.0) 1.00 (0.47-1.53) 272 249
All cancers 1,117 12.1 1,257 462.2 (431.9-492.6) 1.06 (1.00-1.13) 3.5 3.8
1Standardised incidence ratio in relation to all NSW females.
2Cumulative risk.
3Directly age-standardised to 2001 Australian census population.
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Figure 3 Age-speciﬁc cancer incidence andmortality, per
100,000 Aboriginal and non-Aboriginal males and females,
NSW, 1999-2007.
degree-of-spread cancers is signiﬁcantly higher. This can
be seen more clearly by examining mortality to incidence
(M:I) ratios. In Aboriginal males theM:I ratio for localised
cancer is 0.32 compared to 0.21 in non-Aboriginal males;
in Aboriginal females the M:I ratio is 0.23, compared to
0.12 in non-Aboriginal females. For regional degree-of-
spread cancers, these ratios are 0.32 versus 0.17 in males,
and 0.25 versus 0.14 in females; for metastatic cancer the
M:I ratios are 0.49 versus 0.28 in males, and 0.32 versus
0.19 in females; and for cancer of unknown origin the M:I
ratios are 0.52 versus 0.32 in males and 0.25 versus 0.16.
Thus not all the excess mortality from cancer in Aborigi-
nal people is explained by higher cancer stage at diagnosis.
Mortality outcomes for Aboriginal people diagnosed with
cancer of the same degree of spread are signiﬁcantly and
substantially worse than in non-Aboriginal people.
Cancer-speciﬁc Survival
Survival from cancer in Aboriginal people is worse: at 5
years, 35% of non-Aboriginal people in NSW have died
from their cancer, compared to 47% of Aboriginal peo-
ple (Figure 5, Table 6). When viewed as hazard ratios,
adjusted for age and year of diagnosis and cancer degree of
spread, Aboriginal people had an estimated hazard ratio
of dying from cancer of 1.62 (p<.0001). In males, 51% of
Aboriginal cancer cases have died of the cancer at 5 years
compared to 36% of non-Aboriginal cancer cases. The
corresponding male hazard ratio was 1.65 (p<.0001). For
females the proportions surviving 5 years were 43% versus
33%, and the corresponding female hazard ratio was 1.59
(p<.0001). Cancers showing signiﬁcantly lower survival in
Aboriginal people include head and neck (males), stom-
ach (females), large bowel and lung (males and females),
breast and cervix. Of note, the largest Aboriginal/non-
Aboriginal diﬀerence in 5-year cancer survival is in head
and neck cancer among males (41% versus 67%), but in
females this is identical (68%). Notable also are diﬀerences
in survival from lung cancer: a similar proportion (91%) of
Aboriginal males and females with lung cancer had died of
it after 5 years, compared to 85% of non-Aboriginal male
lung cancer cases and 81% of non-Aboriginal female lung
cancers.
Sensitivity Analysis
If Aboriginals comprised 1% of cancer records with miss-
ing Aboriginal status missing, then the estimate of cancer
incidence is 735 per 100,000 males and 481 per 100,000
females, with corresponding male and female SIRs of 1.16
and 1.07 and cumulated risks to 75 years of 1 in 2.5 and 1
in 3.4 respectively (Table 7). These estimates exceed those
imputed here and of course increase with higher propor-
tions of cancers with missing Aboriginality assigned as
Aboriginal (cf. Tables 2 and 3).
Discussion
Based on an extensive assessment of NSW CCR records,
Aboriginality recording rates were found to exceed 98%
for NSW cancer mortality data from 1999 onwards,
meaning that NSWAboriginal cancer mortality occurring
from 1999 can be reliably estimated without imputa-
tion. Aboriginal status recording in non-decedent cancer
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Table 4 Cancer mortality in Aboriginal males, NSW, 1999-2007, and risk comparison with non-Aboriginal males
Mortality rate1 Risk3 to age 75, 1 in:
per 100,000 SMR2 Non-
Cancer site Deaths (95% CI) (95% CI) Aboriginal Aboriginal
Head and neck 54 20.6 (14.5-28.0) 3.18 (2.39-4.15) 56 155
Oesophagus 25 12.9 (7.6-20.1) 2.31 (1.50-3.42) 86 241
Stomach 34 21.2 (13.5-31.1) 2.09 (1.45-2.92) 71 165
Large bowel 68 38.6 (28.0-51.2) 1.40 (1.08-1.77) 45 52
Liver 20 7.8 (4.2-12.8) 1.74 (1.06-2.68) 135 250
Pancreas 30 19.0 (11.6-28.7) 1.70 (1.15-2.42) 94 147
Lung 164 91.1 (75.3-108.8) 1.99 (1.69-2.31) 14 29
Melanoma of skin 12 8.1 (3.5-15.0) 0.67 (0.35-1.17) 174 173
Prostate 65 57.1 (42.6-74.5) 1.86 (1.43-2.37) 51 86
Kidney 19 10.5 (5.4-17.8) 1.70 (1.02-2.66) 159 254
Bladder 10 7.3 (2.8-14.6) 1.12 (0.54-2.06) 366 316
Brain 14 4.4 (1.7-8.4) 0.76 (0.42-1.28) 346 191
Non-Hodgkin’s lymphoma 18 7.9 (4.0-13.6) 1.09 (0.64-1.72) 169 176
All leukaemias 27 16.0 (9.3-25.1) 1.44 (0.95-2.10) 115 185
Unknown primary 48 25.1 (17.1-35.0) 1.86 (1.37-2.46) 57 106
All cancers 657 372.9 (338.9-409.0) 1.68 (1.55-1.81) 4.7 7.5
1Directly age-standardised to 2001 Australian census population.
2Standardised mortality ratio in relation to all NSWmales.
3Cumulative risk.
incidence data has improved markedly over 1996-99.
Despite the improvement, imputation remains necessary
for estimating cancer incidence and cancer survival in
NSW Aboriginal people. For cancers overall, including
decedent cases, unknown Aboriginal status aﬀected 12-
14% of cancer records over 1999-2007, but for cancers
with good survival and/or little or no contact with the hos-
pital system, missing Aboriginal status remains high (for
example, ≈ 44% of all melanomas and 20% of all prostate
cancers). With imputation, the estimated number of can-
cers in NSW Aboriginal people increased by 12-13% over
that oﬃcially recorded. For melanoma and prostate can-
cer, imputation increased numbers of Aboriginal cases by
92% and 31% respectively.
Cancer incidence is 9% and 6% higher in NSW Aborigi-
nal males and females than in all NSW males and females
respectively, and corresponding cancer mortality is 68%
and 73% higher. However, not all the Aboriginal cancer
mortality excess is attributable to more advanced cancer
at diagnosis: despite slightly lower incidence of localised
cancer in Aboriginal people compared to non-Aboriginal
people, mortality from localised cancer is signiﬁcantly
higher, and excess Aboriginal mortality from regional and
distant cancer exceeds that expected from the underlying
excess of incidence in these cancers. At 5 years following
a cancer diagnosis, Aboriginal people are 34% more likely
to have died from the cancer than non-Aboriginal people.
Notably, most of the excess of Aboriginal cancer inci-
dence and mortality occurs in the oldest age groups
and illustrates why diﬀerent measures of incidence and
mortality can be somewhat misleading. For instance,
when directly age-standardised incidence and mortality
rates are compared, as in a ratio of directly standard-
ised rates in Aboriginal people to the total population
(data for the latter not shown), then the excess inci-
dence is 16-17%, substantially higher than the SIR-based
estimates of 6-9%. However, excess mortality when esti-
mated this way is 66-69%, the latter being closer to the
SMRs reported here. Instead we have reported excesses
in Aboriginal cancer incidence and mortality as indi-
rectly standardised ratios and also as cumulated risk esti-
mates which provide estimates less prone to artefacts of
widely diﬀering age distributions in the populations under
comparison.
However, the age distribution of cancer incidence and
mortality in Aboriginal people highlights a broader issue
in Aboriginal health and mortality: the denominator pop-
ulations of older Aboriginal age groups are small because
they comprise those who have survived premature mor-
tality from cardiovascular, endocrine, respiratory and
other chronic diseases. Consequently, cancer has become
a more prevalent cause of death in older Aboriginal age
groups by default. Thus while the excess of morbidity and
mortality rates from preventable cancers in Aboriginal
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Table 5 Cancer mortality in Aboriginal females, NSW, 1999-2007, and risk comparison with non-Aboriginal females
Mortality rate1 Risk3 to age 75, 1 in:
per 100,000 SMR2 Non-
Cancer site Deaths (95% CI) (95% CI) Aboriginal Aboriginal
Head and neck 18 6.8 (3.8-11.1) 3.21 (1.90-5.07) 135 608
Oesophagus 11 4.5 (2.0-8.5) 2.40 (1.20-4.29) 316 787
Stomach 17 7.9 (4.2-13.2) 1.98 (1.15-3.16) 235 433
Large bowel 49 23.6 (16.7-32.2) 1.24 (0.92-1.64) 81 87
Liver 10 4.6 (2.0-8.9) 2.19 (1.05-4.03) 260 768
Pancreas 29 15.0 (9.6-22.2) 1.82 (1.22-2.61) 118 201
Lung 134 57.8 (47.4-69.6) 2.73 (2.29-3.23) 25 62
Melanoma of skin 9 4.1 (1.6-8.2) 1.00 (0.46-1.89) 325 442
Breast 99 35.6 (28.0-44.4) 1.54 (1.25-1.88) 37 59
Cervix 31 10.9 (6.8-16.2) 4.74 (3.22-6.73) 123 663
Uterus 13 6.4 (3.1-11.5) 2.05 (1.09-3.51) 259 490
Ovary 22 8.3 (4.8-13.1) 1.35 (0.84-2.04) 157 203
Kidney 16 6.9 (3.6-11.7) 2.36 (1.35-3.82) 188 469
Brain 15 5.5 (2.7-9.7) 1.20 (0.67-1.98) 208 315
Non-Hodgkin’s lymphoma 13 5.3 (2.5-9.6) 1.00 (0.53-1.72) 213 277
All leukaemias 15 5.4 (2.5-9.6) 1.17 (0.66-1.94) 389 345
Unknown primary 35 14.4 (9.4-20.8) 1.35 (0.94-1.88) 103 138
All cancers 572 240.3 (218.5-263.5) 1.73 (1.59-1.88) 6.5 11.1
1Directly age-standardised to 2001 Australian census population.
2Standardised mortality ratio in relation to all NSW females.
3Cumulative risk.
people needs to be addressed, a substantial contributor to
both incidence and mortality from cancer in Aboriginal
people is excess mortality from non-cancer causes.
Possible explanations for the mortality excess over what
may be expected from incidence or late stage at diagnosis
include likely higher prevalence of co-morbid conditions
in Aboriginal people which often precludes more eﬀective
cancer treatment, for example, organ resection. However,
other factors likely also contribute to lower cancer sur-
vival in Aboriginal people. A study of lower survival from
cervical cancer in New Zealand Maori women found that
co-morbidity associated with cervical cancer explained
only a moderate proportion of survival diﬀerences [8].
Access to eﬀective treatment is an issue for many Aborig-
inal people where geographic remoteness, limited access
to transport and accommodation are major issues [9,10],
especially for treatment requiring extended periods of
stay away from home and community, without support or
facilities to cater for visits from large or extended families
[11].
There is also evidence that many Aboriginal people are
less likely to take up and adhere to some cancer thera-
pies and treatments, often for cultural reasons, but also
from negative experiences with the health system [12-14].
Importantly, a Western Australian study has found a
deep sense of cancer fatalism to exist in many Aboriginal
people, who perceive cancer as ‘a form of punishment
resulting from some misdeed the person had done in
the past’; as something that cannot be prevented; ‘equals
death’; and is ‘god’s will’ [15]. Such cancer fatalism was
found often to be accompanied by unrealistic expecta-
tions of treatment, and one consequence was that check
ups following treatment are missed because the patient
believes that they are cured [15]. It is thus probable that
lower survival in Aboriginal people from cancers detected
at the same stage and undergoing the same treatment
as non-Aboriginal people may be due to lack of ade-
quate follow-up and monitoring after treatment. Given
that cancer treatment also often involves feelings of ill-
ness and unwellness, it is also probable that some Abo-
riginal people would perceive the treatment to be not
working for them individually but doing harm. However,
without deﬁnite knowledge of Aboriginal/non-Aboriginal
co-morbidity and cancer treatment diﬀerences, includ-
ing adherence, these explanations remain plausible at
best.
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However, an area in need of investigation is pharma-
cogenomic: to what extent can poorer cancer treatment
outcomes in Aboriginal people be attributable to genetic
factors that might inﬂuence response to anti-cancer
drugs, including eﬃcacy and toxicity. Ethnic diﬀerences in
response to irinotecan (for treatment of a broad range of
carcinomas including of the bowel and lung), gemcitabine
(for treatment of solid tumours) and tamoxifen (for breast
cancer) have been observed between Caucasians, Africans
and Asians, and speciﬁc genetic factors isolated [16]. The
genetic factors uncovered thus far do not account for
all the variation by these ethnic groups, but personalised
irinotecan therapy has been implemented in the US, Japan
and Singapore [16]. Genetic studies of Aboriginal people
Figure 4 Age-standardised cancer incidence andmortality by degree of spread at diagnosis, Aboriginals and non-Aboriginals, males and
females, 1999-2007.
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Figure 5 Survival from cancer in Aboriginals and non-Aboriginals, persons, males and females, 1999-2007.
in relation to common anti-cancer agents have yet to be
conducted.
Our estimates of SIRs for Aboriginal people are higher
than those recently estimated for Queensland [4], where
male cancer incidence was estimated to be 28% lower than
for all Queensland males (SIR = 0.72), and 15% lower
for Aboriginal females (SIR = 0.85), compared to all-
Queensland females. Most of the lower cancer incidence
in Queensland Aboriginal people was attributed to lower
rates of colorectal, prostate, breast and skin cancers than
non-Aboriginal people.
In contrast, the present study found bowel cancer not
to be signiﬁcantly diﬀerent in NSW Aboriginal compared
to non-Aboriginal people. Melanoma SIRs for NSW Abo-
riginal males and females were estimated in the present
study to 0.44 and 0.47, signiﬁcantly higher than 0.06 and
0.07 for Queensland Aboriginal males and females respec-
tively. While the Queensland study did not report abso-
lute incidence rates for individual cancers, the counts of
melanoma cases over a 10-year study period were about
one third to half of the estimates in the present study for
NSW covering a 9-year study period. The imputation pro-
cess may have led to an over-estimate of of melanoma
incidence in NSW Aboriginal people. However, the much
lower melanoma SIR for Queensland would also partly
be a consequence of higher melanoma incidence rates in
the overall population of Queensland compared to NSW
[17-19].
The present study found most cancers with excess inci-
dence among Aboriginal people to be the same as those
reported in the Queensland study. However, ovarian can-
cer incidence was found not to be signiﬁcantly higher than
in non-Aboriginal women, and head and neck cancers
were over-represented in NSW Aboriginal people of both
sexes, which in Queensland was limited to Aboriginal
males [4].
Aboriginal people comprise 2.2% of the NSW popula-
tion [1] and if a similar proportion were assumed to be
representative of Aboriginal people in cancers with miss-
ing Aboriginal status, then from the sensitivity analysis
(Table 7), Indigenous cancer incidence would be con-
siderably higher than the estimates presented here. On
this criterion, our estimates of Aboriginal cancer inci-
dence here are somewhat conservative and suggest that
Aboriginal people comprise <1% of cancers with missing
Aboriginal status and consequently are more likely to have
their Aboriginal status recorded in cancer registration
than non-Aboriginal people.
Estimates of all-cancer mortality diﬀerentials in NSW
Aboriginals were higher in the present study compared to
the Queensland study. The latter estimated cancer mor-
tality to be 28% higher in Aboriginal males than the
all-Queensland male population (compared to 68% higher
than NSW males in this study), and 47% higher in Abo-
riginal females than all-Queensland females (compared to
73% higher than NSW females in this study) [4]. Can-
cers contributing most to the Queensland excess were
head and neck, lung, oesophageal, liver, and unspeciﬁed
site (males and females), along with cervix and uterus
in Aboriginal women. These cancers were also the main
contributors to our estimates of excess cancer mortality
in NSW Aboriginal people. While Aboriginal breast can-
cer mortality in the Queensland study was ≈ 25% higher
than all Queensland women, in the present study it was
estimated as 54% higher than all NSW women.
Our estimates of (relative) mortality from cancer in
NSW Aboriginal people are similar to the 2006 NSW
study by Supramaniam et al. for males, where Aboriginal
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Table 6 Five-year cancer-speciﬁc survival (%) and adjusted† hazard ratios in Aboriginal versus non-Aboriginal people,
males and females, NSW, 1999-2007, with 95% conﬁdence intervals
Cancer site Aboriginal Non-Aboriginal Hazard Ratio†
Persons
Head and neck 48.7 (38.4-58.9)*** 65.6 (64.4-66.8) 1.90 (1.46-2.48)***
Stomach 17.1 (5.6-28.6)* 29.6 (28.3-30.9) 1.36 (1.01-1.82)*
Large bowel 50.7 (43.5-57.9)*** 64.9 (64.4-65.4) 1.63 (1.35-1.97)***
Pancreas 4.4 (0.0-10.3) 6.7 (6.0-7.5) 1.32 (1.01-1.73)*
Lung 9.2 (5.4-13.1)** 16.3 (15.8-16.9) 1.47 (1.31-1.66)***
Melanoma of skin 90.6 (84.7-96.5) 90.4 (90.0-90.8) 0.98 (0.52-1.84)
All cancers 52.6 (50.3-55.0)*** 65.4 (65.2-65.5) 1.62 (1.52-1.73)***
Males
Head and neck 40.7 (28.2-53.2)*** 64.7 (63.3-66.2) 2.17 (1.61-2.93)***
Stomach 19.9 (5.7-34.1) 29.6 (28.0-31.3) 1.18 (0.83-1.68)
Large bowel 47.9 (38.1-57.7)* 64.6 (63.8-65.3) 1.74 (1.36-2.22)***
Pancreas 8.0 (0.0-18.4) 6.2 (5.2-7.2) 1.19 (0.81-1.75)
Lung 9.3 (4.3-14.3)* 15.0 (14.4-15.7) 1.43 (1.22-1.67)***
Melanoma of skin 89.0 (80.1-97.9) 88.3 (87.7-88.8) 0.84 (0.37-1.90)
Prostate 77.6 (70.9-84.3)*** 87.7 (87.3-88.1) 1.87 (1.37-2.57)***
All cancers 48.8 (45.5-52.1)*** 64.1 (63.8-64.4) 1.65 (1.51-1.80)***
Females
Head and neck 67.7 (52.4-83.0) 67.7 (65.5-69.9) 1.28 (0.71-2.30)
Stomach 11.4 (0.0-28.9)* 29.5 (27.3-31.8) 1.98 (1.15-3.40)*
Large bowel 54.6 (43.8-65.3)* 65.3 (64.5-66.1) 1.49 (1.11-2.00)*
Pancreas 8.5 (0.0-19.5) 7.2 (6.1-8.3) 1.46 (0.99-2.15)
Lung 8.9 (2.8-15.1)* 18.7 (17.7-19.6) 1.54 (1.30-1.84)***
Melanoma of skin 92.1 (84.3-99.9) 93.3 (92.8-93.8) 1.35 (0.50-3.64)
Breast 79.1 (74.0-84.2)*** 87.8 (87.4-88.2) 1.83 (1.40-2.40)***
Cervix 59.0 (46.0-72.0)* 73.6 (71.5-75.6) 1.96 (1.30-2.96)***
All cancers 56.5 (53.4-59.7)*** 66.9 (66.6-67.2) 1.59 (1.45-1.75)***




male cancer mortality (for 1994-2002) was estimated to be
72% higher than all NSW males, but lower than the 65%
excess estimated for Aboriginal females [3]. In the latter
study, the authors adjusted for missing Aboriginality in
NSW cancer mortality data by inﬂating observed Aborig-
inal cancer deaths by a factor of 100100 − % Aboriginality missing
and calculated the SMR using the resulting inﬂated num-
bers. While this procedure can produce plausible esti-
mates of Aboriginal cancer mortality, the resulting sum
of Aboriginal and non-Aboriginal cancer deaths would
exceed that recorded for the total population.
In summary, the present study is the ﬁrst to provide
estimates of cancer incidence rates in the Aboriginal pop-
ulation of NSW, and the ﬁrst to estimate NSW Aboriginal
cancer mortality without imputation or other adjustment,
the latter based on high completion of recording of
Aboriginal status in cancer mortality data. As this is a
population-based study in a setting of mandatory report-
ing of all malignancies diagnosed in NSW residents, it is
not prone to biases originating from non-representative
samples or from diﬀerential recording of cancers. A
potential weakness of this study has been the assumption
that Aboriginal status is correctly recorded when it is non-
missing. Despite eﬀorts to pro-actively record Aboriginal
status in vital registration and in the NSW health system,
this possibility underscores a need for some validation
studies of Aboriginal status recording across the health
and vital registration settings. More broadly, low rates of
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Table 7 Sensitivity analysis: estimates of Aboriginal cancer incidence, NSW 1999-2007, assuming 1-5% of all cancers with
missing Aboriginal status are Aboriginal
Proportion (%) missing Cases Incidence1 per 100,000 (95%CI) SIR (95% CI) Risk to age
assumed to be Aboriginal 75, 1 in:
Persons
0 2,318 493.4 (469.8-517.6) 0.95 (0.92-0.99) 3.3
1 2,700 587.7 (561.7-614.4) 1.11 (1.07-1.15) 2.9
2 3,083 678.6 (650.5-707.5) 1.27 (1.22-1.31) 2.6
3 3,466 771.6 (741.6-802.5) 1.43 (1.38-1.47) 2.4
4 3,849 864.5 (832.6-897.3) 1.58 (1.53-1.63) 2.2
5 4,232 955.3 (921.6-989.8) 1.74 (1.69-1.79) 2.1
Males
0 1,201 595.2 (554.1-638.1) 0.97 (0.91-1.02) 2.9
1 1,437 734.7 (688.4-782.8) 1.16 (1.10-1.22) 2.5
2 1,649 861.6 (811.0-914.1) 1.33 (1.27-1.39) 2.2
3 1,888 1,000 (945.7-1,057) 1.52 (1.45-1.59) 2.0
4 2,106 1,130 (1,072-1,191) 1.70 (1.63-1.77) 1.9
5 2,335 1,261 (1,199-1,325) 1.88 (1.81-1.96) 1.7
Females
0 1,117 419.7 (391.8-448.8) 0.95 (0.89-1.00) 3.8
1 1,263 481.3 (451.3-512.7) 1.07 (1.01-1.13) 3.4
2 1,434 546.9 (514.8-580.4) 1.21 (1.15-1.28) 3.1
3 1,578 606.0 (572.1-641.3) 1.34 (1.27-1.40) 2.9
4 1,743 672.8 (636.9-710.1) 1.48 (1.41-1.55) 2.7
5 1,897 735.0 (697.4-774.0) 1.61 (1.53-1.68) 2.5
1Directly age-standardised to 2001 Australian census population.
recording of Aboriginal status in cancers not commonly
admitted to hospital (eg, melanoma) highlight important
recording gaps in the health system that stemmainly from
medical practitioners and pathology laboratories which
do not record Aboriginal status.
Conclusion
Despite some uncertainties around the extent of cancer
incidence in NSW Aboriginal people, it is certain that
NSW Aboriginal people suﬀer an unacceptable excess
of preventable cancers, particularly of the lung, digestive
tract and female genital tract. However, a large component
of the excess of cancer incidence and mortality in Aborig-
inal people is occurring in older age groups of survivors,
already depleted by mortality from non-cancer causes
of death. Nonetheless, campaigns and initiatives directed
at lowering risk factors for cancer in Aboriginal people
clearly need to be more eﬀective in addressing the signif-
icant social, economic, geographical and cultural barriers
that prevent Aboriginal people from lowering their risk of
acquiring preventable cancers. Maximising survival once
cancer is diagnosed and treated in Aboriginal people may
also need targeted therapies based on pharmacogenomic
studies.
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